

**Full Title:** Assessing how women access healthcare to inform cervical cancer and HIV screening in rural Uganda.

**Authors:** Mia Sheehan<sup>1,2</sup>, Hallie Dau<sup>2,3</sup>, Maryam AboMoslim<sup>2,3</sup>, Priscilla Naguti<sup>4</sup>, Nelly Mwandacha<sup>1,2</sup>, Amy Booth<sup>2</sup>, Candice Ruck<sup>2,3</sup>, Laurie Smith<sup>2,5</sup>, Jackson Orem<sup>4</sup>, Gina Ogilvie<sup>2,3,6</sup>, Carolyn Nakisige<sup>4</sup>

**Affiliations:** <sup>1</sup>Simon Fraser University, Burnaby, Canada;  
<sup>2</sup>Women's Health Research Institute, Vancouver, Canada;  
<sup>3</sup>School of Population and Public Health, UBC, Vancouver, Canada;  
<sup>4</sup>Uganda Cancer Institute, Kampala, Uganda;  
<sup>5</sup>BC Cancer, Vancouver, Canada;  
<sup>6</sup>BC Centre for Disease Control, Vancouver, Canada.

**Corresponding author:** Gina Ogilvie, MD MSc FCFP DrPH  
BC Women's Hospital and Health Centre  
Box 42, Room H203G - 4500 Oak Street  
Vancouver, BC, V6H 3N1  
(604) 875-2424 Ext 6488  
Gina.Ogilvie@bccdc.ca

1 **Author contributions:** MS (formal analysis, writing—original draft, writing—review and editing);  
2 HD (formal analysis, writing—original draft, writing—review and editing); MA (writing—review and  
3 editing); PN (project administration, data collection, writing—review and editing); NM (formal  
4 analysis, writing—review and editing); AB (writing—review and editing); CR (writing—review and  
5 editing); LS (writing—review and editing); JO (writing—review and editing); GO (principal  
6 investigator, conceptualization, funding acquisition, writing—review and editing); CN  
7 (conceptualization, project administration, writing—review and editing); All authors have read and  
8 approved the manuscript, and fulfil all four criteria for authorship.

9

10

## 11 **ABSTRACT**

### 12 **Objective**

13 This study aims to compare how HIV-positive and HIV-negative women in a remote sub-country in  
14 Uganda access health services to inform consideration of potential HIV and HPV-based cervical  
15 cancer screening integration at the community level.

### 16 **Methods**

17 This cross-sectional study recruited women living in the South Busoga District Reserve from January  
18 to August 2023. Women were eligible if they were aged 30 to 49 years old, had no history of cervical  
19 cancer screening or treatment, had no previous hysterectomy, and could provide informed consent.  
20 Participants completed a survey administered by village health teams, which included questions on  
21 HIV status, demographics, healthcare access, and services received. The data was analyzed using  
22 bivariate descriptive statistics, including chi-square and Fisher's exact tests.

### 23 **Results**

24 Among the 1437 participants included in the analysis, 8.8% were HIV-positive. The majority of the  
25 respondents were between 30-39 years of age, were married, had received primary education or  
26 higher, and were farmers. The majority of women in both groups had accessed outreach visits (HIV-  
27 positive = 89.0%, HIV-negative = 85.8%) and health centres (HIV-positive = 96.1%, HIV-negative  
28 = 80.2%). The most commonly received services among both groups of women at outreach visits  
29 and health centres were immunization and antenatal care, respectively.

### 30 **Conclusion**

31 Our study demonstrated that there were no significant differences in healthcare access between  
32 HIV-positive and HIV-negative women in rural Uganda. Additionally, the high usage of healthcare  
33 services by women living with HIV suggests that the integration of cervical cancer and HIV

34 screening may facilitate early detection and prevention of cervical cancer among this population.

35 This can reduce the burden of disease in Uganda and further contribute to the World Health

36 Organization’s initiative to eradicate cervical cancer.

37

38 **Keywords:** Cervical cancer, Uganda, LMIC, HIV, HPV-based screening

39

## 40 Introduction

41 Cervical cancer is the most common cancer among women in low- and middle-income countries  
42 (LMICs). (1, 2). Despite cervical cancer being almost entirely preventable and treatable (2), LMICs  
43 face a significant burden of disease as prevention efforts such as vaccination and screening services  
44 are often limited (3, 4). Exacerbating the disproportionate burden of cervical cancer in LMICs, women  
45 are often diagnosed at advanced stages and are unable to receive effective treatment due to limited-  
46 service accessibility and availability (5). Uganda has one of the highest incidence rates of cervical  
47 cancer in the world, with 56.2 reported cases per 100,000 women (3).

48 In 2020, the World Health Organization (WHO) announced its global strategy to eliminate cervical  
49 cancer (6), with a key target of 70% of women screened with high-performance screening tests by the  
50 age of 35 (6). Although cervical cancer is one of the leading causes of morbidity and mortality among  
51 women in Uganda, less than 10% of women have been screened (5), highlighting the urgent need for  
52 an accessible screening program across the country. Many women in LMICs also experience personal,  
53 logistical, and healthcare system barriers, leading to a low rate of screening uptake (8). Self-collected  
54 human papillomavirus (HPV)-based cervix screening has been proposed as an effective and cost-  
55 efficient alternative strategy to overcome existing barriers to cervical cancer screening and further  
56 reduce cervical cancer rates in LMICs (9,10).

57 HPV-based cervical cancer screening allows for the identification of high-risk HPV, which is a primary  
58 cause of cervical cancer (1). Self-collection offers a less invasive, low-barrier approach to cervical  
59 screening that can be performed by women on their own, in the privacy of their homes or wherever  
60 convenient (11). It has been shown to be as accurate as cervical samples collected by clinicians and  
61 more sensitive than visual inspection with acetic acid (VIA), which is currently the most commonly  
62 used method to screen women in LMICs (11-13). With these benefits, HPV-based screening may

63 allow for increased access and coverage of high-quality cervical cancer screening in LMICs, such as  
64 Uganda (12).

65 Women living with human immunodeficiency virus (HIV) are six times more likely to develop invasive  
66 cervical cancer compared to women without HIV infections, making cervical cancer prevention  
67 among this population a key priority (1,14,15). Additionally, women living with HIV face many  
68 barriers to accessing health services such as financial burdens (16), limited awareness (17) availability  
69 of specialized care (16), and social stigma (16,18). Ensuring access to cervical cancer screening for  
70 HIV-positive women may contribute to reducing HIV-attributable cervical cancer cases, and further  
71 alleviate the heightened burden of disease in Uganda (19). To effectively facilitate cervical cancer  
72 prevention amongst this population, the integration of HIV and HPV-based cervical cancer screening  
73 may be beneficial. Sarah Maria et al. found that less than half of HIV-positive women in urban Uganda  
74 had ever been screened for cervical cancer (20), a number that is likely to be lower in rural areas.  
75 Integration could ultimately reduce barriers, specifically among women living in rural Uganda who  
76 experience additional challenges such as long distances to health facilities and lack of health  
77 information access (21). Additionally, literature from LMICs demonstrates that integration can  
78 improve the utilization of both HIV care and cervical cancer screening services, alleviate stigma, and  
79 enhance the overall quality of care received by patients (22).

80 The potential for successful and effective integration of HIV and HPV-based cervical cancer screening  
81 services in Uganda relies on multiple factors, including understanding how women with HIV currently  
82 access health services compared to women without HIV. However, there is limited research on this  
83 topic, particularly in rural areas. The objective of this study is to compare how HIV-positive and HIV-  
84 negative women in a remote sub-country in Uganda access health services to inform consideration of  
85 potential HIV and HPV-based cervical cancer screening integration at the community level.

## 86 **Methods**

### 87 *Design, Setting, and Study Population*

88 This cross-sectional study is part of a pragmatic cluster-randomized trial in Malongo, a rural and  
89 remote sub-county within the Mayuge district of Uganda focused on HPV-based self-collection for  
90 cervical cancer screening. The survey data used for this study is part of a baseline survey given to  
91 participants at enrollment in the pragmatic trial to assess knowledge and attitudes about cervical cancer  
92 and screening. Women were recruited door-to-door by village health teams (VHTs) between January  
93 23 to August 24, 2023 from eleven villages in the South Busoga Forest Reserve in Malongo. Women  
94 were eligible for the study if they were aged 30-49 years old, had not previously been screened for  
95 cervical cancer, did not have a previous hysterectomy, and could provide informed consent. VHTs  
96 administered the survey on REDCap software (23) using electronic tablets to ensure secure data  
97 collection. All questions were read aloud in Lusoga or English, based on the language preference of  
98 the participant.

### 99 *Survey*

100 The survey tool used in this study is informed by the Improving Data for Decision Making in Global  
101 Cervical Cancer Programs Toolkit-Part 2 (IDCCP) (24). The survey included questions on participant  
102 demographics, medical history, knowledge about cervical cancer, and perceived barriers to screening.

103 The explanatory variable used in the study was self-reported HIV status. Participants of the survey  
104 were asked if they had ever tested positive for HIV and responded with either yes, no, or prefer not  
105 to say. Women who answered yes (HIV-positive) or no (HIV-negative) were included in the study.

106 Several variables were used to assess the outcome of access to health services. First, we asked women  
107 whether they had attended either a healthcare outreach visit or visited a health centre. Healthcare  
108 outreach visits included organized community health events or other instances where health services  
109 were available at the community level. Health centres refer to established clinics or hospitals that  
110 deliver healthcare services to patients. Response options for both variables were yes, no, and do not  
111 know. If a woman indicated do not know, it was recoded as no. Women were asked what services  
112 they received at the outreach visit and health centre visit, if applicable. Response options for both  
113 variables were antenatal, HIV, family planning, immunization, and other. Additionally, if applicable,  
114 women were asked about how they were recruited to a health outreach visit. Response options  
115 included: VHTs, radio, and other, which combined community leader, community member,  
116 family/friend, and other. Women were also asked, if applicable, how they traveled to health centers.  
117 Response options included: walking, boda boda, and other.

118 Secondly, several variables related to cervical cancer screening were included to assess the potential  
119 integration of HIV care and cervical cancer screening. These variables included: prior awareness of  
120 cervical cancer, the barriers to cervical cancer screening (did not know how/where to get the test,  
121 embarrassment, too expensive, didn't have time, clinic too far away, poor service quality, afraid of the  
122 procedure, afraid of social stigma, cultural beliefs, family member would not allow, other, do not  
123 know), and perceived importance of early cervical cancer detection.

124 The following demographic variables were included in the analysis: survey language, age, education  
125 level, occupation, relationship status, partner education level, age at first pregnancy, and number of  
126 pregnancies.

127 *Data analysis*



128 Bivariate descriptive statistics were used to analyze the findings of the survey data collected in the  
129 study. All missing values were included in the results. Chi-square and Fisher's exact test were used to  
130 determine statistically significant variables (25). P-values  $\leq 0.05$  were considered statistically significant.  
131 R Studio (R 4.3.0) was used to conduct the analysis (26).

### 132 *Ethics Statements*

133 Ethics approval was obtained from the University of British Columbia Children's and Women's  
134 Research Ethics Board (H22-01634), the Uganda Cancer Institute Research Ethics Committee (UCI-  
135 2022-56), and the Uganda National Council for Science and Technology. All participants provided  
136 informed consent for their inclusion in the study.

### 137 **Results**

138 Overall, 1437 participants completed the survey, of which 127 women were HIV-positive (8.8%). The  
139 majority of the respondents in both groups (HIV-negative and HIV-positive) were between 30-39  
140 years of age, had obtained primary education or more (HIV-positive n=76, 59.8%; HIV-negative  
141 n=900, 68.7%; p=0.123), were married (HIV-positive n=107, 84.3%; HIV-negative n=1136, 86.7%;  
142 p=0.865), and were farmers (HIV-positive n=99, 78.0%; HIV-negative n=1117, 85.3%; p=0.06).

143 Additional information on the demographic characteristics of the survey respondents is provided in

#### 144 **Table 1.**

145 When participants were asked about their history of attendance at healthcare outreach visits, the  
146 majority of women, regardless of their HIV status, responded yes to attending (HIV-positive n=113,  
147 89.0%; HIV-negative n=1124, 85.8%; p=0.596). Among the 1237 women who attended a health  
148 outreach visit, immunization was reported as the most commonly accessed service for both groups  
149 (HIV-positive n=59, 46.5%; HIV-negative n=551, 42.1%; p=0.388), followed by antenatal care (HIV-

150 positive n=47, 37.0%; HIV-negative n=517, 39.5%; p=0.655). When asked about how they were  
151 informed of health care outreach visits, the vast majority in both groups indicated VHT (HIV-positive  
152 n=102, 80.3%; HIV-negative n=1051, 80.2%; p=0.036).

153 More women attended a health centre than healthcare outreach visits (HIV-positive n=122, 96.1%;  
154 HIV-negative n=1267, 96.7%; p=0.289). Among the 1389 women who attended a health center,  
155 antenatal care was reported as the most commonly accessed service for both groups (HIV-positive  
156 n=79, 62.2%; HIV-negative n=839, 64.0%; p=0.752) followed by HIV services for HIV-positive  
157 women (HIV-positive n=41, 32.3%; p<0.001) and family planning for HIV-negative women (HIV-  
158 negative n=311, 23.7%; p=0.749) (**Table 2**). The respondents in both groups reported relying mainly  
159 on walking as their primary means of transportation to reach health centres (HIV-positive n=84,  
160 66.1%; HIV-negative n=839, 64.0%; p=0.373).

161 The majority of women across both groups answered that they had prior awareness of cervical cancer  
162 (HIV-positive n= 103, 81.1%; HIV-negative n= 1137, 86.8%; p=0.321). Furthermore, the majority  
163 believed that early detection was important (HIV-positive n= 116, 91.3%; HIV-negative n= 1185,  
164 90.6%; p=0.01). When asked about the barriers to screening (**Figure 1**), the most common response  
165 among both groups was not knowing where to get tested (HIV-positive n= 37, 29.1%; HIV-negative  
166 n= 522, 39.8%) followed by the cost (HIV-positive n= 36, 28.3%; HIV-negative n= 356, 27.2%), and  
167 prohibitive distance to the clinic (HIV-positive n= 19, 15.0%; HIV-negative n= 191, 14.6%) (p=0.023).

## 168 **Discussion**

169 This study aimed to assess the differences in healthcare access by HIV status. We found that the  
170 majority of women in both HIV-positive and HIV-negative groups attended health care outreach  
171 visits and health centres and utilized similar services at both.

172 The majority of HIV-positive and HIV-negative women had prior awareness of cervical cancer and  
173 understood the importance of early cervical cancer detection. The lack of cervical cancer knowledge  
174 is likely not a barrier to accessing screening among never-screened women in Malongo. Research  
175 conducted in Zimbabwe (27), Ghana (28), and Western Uganda (29) on cervical cancer knowledge  
176 and attitudes of women found that women generally had good levels of understanding of HPV,  
177 cervical cancer, and screening (27-29). However, findings demonstrated that knowledge and  
178 information on cervical cancer did not lead to behaviour change for screening, as represented by the  
179 low rates of screening among the women in these countries (27, 29). Additionally, there was no  
180 significant difference in knowledge between HIV-positive and HIV-negative women (28). In Uganda,  
181 cervical cancer screening rates are less than 10% (5), despite the findings of our study indicating  
182 widespread awareness of cervical cancer in women, regardless of HIV status. There is a need for  
183 programming to bridge the gap between knowledge and behaviour change to ensure that awareness is  
184 translated into increased screening to alleviate the burden of disease among women in Uganda (30).

185 The majority of women in both groups who attended health outreach visits were informed about these  
186 visits by VHTs. Current literature demonstrates the critical role that VHTs play in disseminating health  
187 information and facilitating access to health services in Uganda (31). As a primary point of contact for  
188 health and social services, VHTs assist community members in understanding available healthcare  
189 services and options and mobilize individuals in the community to actively participate in accessible  
190 health programs (31, 32). Their role in the healthcare of Uganda can help overcome barriers to  
191 participation and encourage community members to access services available to them. The findings  
192 from our study along with the evidence provided in the literature suggest that VHTs could play a  
193 critical role in raising awareness of HPV-based cervical cancer screening and available screening  
194 options in both HIV-positive and negative populations. Moreover, VHTs may contribute to the

195 promotion and establishment of the successful integration of HIV and HPV-based cervical cancer  
196 screening services in rural communities.

197 Our study indicated that all women had a history of pregnancy and that a high proportion of HIV-  
198 positive and HIV-negative women had received antenatal services. Studies that have shown a high  
199 rate of attendance to antenatal care among pregnant women in Uganda (34). In addition to the notable  
200 overlap of the age of women attending antenatal care and the age of women recommended to be  
201 screened for cervical cancer (35), pregnancy is a period where women experience heightened medical  
202 supervision and prioritize their own health conditions (36). Furthermore, women attending antenatal  
203 care show a strong commitment to adhere to follow-up visits and care instructions throughout their  
204 pregnancy (37). Therefore, the antenatal period may provide an opportunity for increased uptake of  
205 HPV-based cervical cancer screening, both in HIV-negative and HIV-positive women in Uganda (36).

206 Given that HIV-positive women are at a higher risk for developing cervical cancer, it is critical to  
207 prioritize and cervical cancer prevention amongst this population (1,13,14). Investigating the  
208 differences in healthcare access and service utilization between HIV-positive and HIV-negative  
209 women allows for a better understanding of additional barriers that women living with HIV may be  
210 facing in accessing cervical cancer prevention services. This study highlighted that there were no  
211 significant differences in health service access and usage between HIV-positive and HIV-negative  
212 women. This demonstrates the ways in which women living with HIV are generally similarly engaged  
213 with the healthcare system in rural Uganda compared to HIV-negative women. This may further  
214 suggest that health inequities faced by women living with HIV are not being exacerbated by barriers  
215 to accessing and utilizing available health services, suggesting that lack of access does not fully explain  
216 the low uptake rates of cervical cancer screening reported among HIV-positive women (20). These  
217 findings can inform additional investigation into the barriers that prevent the uptake of cervical cancer

218 screening in this population., as well as the development of a comprehensive HPV-based cervical  
219 cancer screening in Uganda that effectively targets women regardless of their HIV status. Further, this  
220 may lead to increased access to reproductive services among both HIV-positive and negative women  
221 in rural and remote communities, allowing for expanded health access for all. Integrated, concurrent  
222 screening for HIV and HPV may be more effective in the early detection and treatment of pre-  
223 cancerous lesions among women living with HIV, reducing the burden of disease that these women  
224 face (40).

225 The findings of this study are strengthened by the experience and the expertise of the study team.  
226 Additionally, study recruitment and survey administration were also conducted door-to-door, meaning  
227 women were involved in the study from the safety and comfort of their own homes. Despite the  
228 strengths of this study, some limitations exist. As the prevalence of HIV was much higher in the  
229 women who were surveyed in comparison to the population data of women living in Uganda, the  
230 results of this study may not be generalizable (41). This difference in HIV prevalence may be due to  
231 self-reporting of HIV status, which could impact the results of the study. Similarly, the collected survey  
232 data was based on self-reported information, which may be subject to response biases that influence  
233 the results of the study (42). As women in the study responded to the survey questions to VHTs  
234 verbally, this may have resulted in social desirability bias (43).

235 The results from our study demonstrate that women in remote Uganda had high attendance to health  
236 services offered at both outreach visits and health centres, with no significant differences between  
237 HIV-positive and HIV-negative women. Further research is needed on how to effectively integrate  
238 HIV and HPV-based cervical cancer screening programs into rural health systems at the community  
239 level.

240

241 **Conflict of interests**

242 The authors declare that they have no competing interests.

243

244 **Funding**

245 Funding for this project was provided by the Canadian Institutes of Health Research (CIHR FDN-

246 143339) and BC Women's Health Foundation. Hallie Dau received a Canada Graduate Doctoral

247 Award from the Canadian Institutes of Health Research for salary support. The funders had no role

248 in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

249

250

251

252

253

254

255

256

257

258

## References

- 259 1. Cervical cancer [Internet]. World Health Organization; 2020 [cited 2023 Jun 20]. Available  
260 from: <https://www.who.int/news-room/fact-sheets/detail/cervical-cancer>
- 261 2. Mitchell S, Ogilvie G, Steinberg M, Sekikubo M, Biryabarema C, Money D. Assessing  
262 women's willingness to collect their own cervical samples for HPV testing as part of the  
263 ASPIRE cervical cancer screening project in Uganda. *International Journal of Gynecology  
264 & Obstetrics*. 2011;114(2):111–5.
- 265 3. Gottschlich A, Payne BA, Trawin J, Albert A, Jeronimo J, Mitchell-Foster S, et al.  
266 Community-integrated self-collected HPV-based cervix screening in a low-resource rural  
267 setting: a pragmatic, cluster-randomized trial. *Nat Med*. 2023 Apr;29(4):927–35.
- 268 4. Mitchell SM, Sekikubo M, Biryabarema C, Byamugisha JJK, Steinberg M, Jeronimo J, et al.  
269 Factors associated with high-risk HPV positivity in a low-resource setting in sub-Saharan  
270 Africa. *American Journal of Obstetrics and Gynecology*. 2014 Jan;210(1):81.e1-81.e7.
- 271 5. Hull R, Mbele M, Makhafola T, Hicks C, Wang S, Reis R, et al. Cervical cancer in low and  
272 middle-income countries (Review). *Oncol Lett*. 2020 Jun 19;20(3):2058–74.
- 273 6. WHO Global strategy to accelerate the elimination of cervical cancer as a public health  
274 problem [Internet]. World Health Organization; 2020 [cited 2023 Jun 29]. Available from:  
275 <https://www.who.int/publications/i/item/9789240014107>
- 276 7. Mungo C, Barker E, Randa M, Ambaka J, Osongo CO. Integration of cervical cancer  
277 screening into HIV/AIDS care in low-income countries: a moral imperative.  
278 *Ecancermedalscience*. 2021 May 20;15:1237.
- 279 8. Teng FF, Mitchell SM, Sekikubo M, Biryabarema C, Byamugisha JK, Steinberg M, et al.  
280 Understanding the role of embarrassment in gynaecological screening: a qualitative study  
281 from the ASPIRE cervical cancer screening project in Uganda. *BMJ Open*. 2014 Apr  
282 1;4(4):e004783.
- 283 9. Oketch SY, Kwena Z, Choi Y, Adewumi K, Moghadassi M, Bukusi EA, et al. Perspectives  
284 of women participating in a cervical cancer screening campaign with community-based  
285 HPV self-sampling in rural western Kenya: a qualitative study. *BMC Women's Health*. 2019  
286 Jun 13;19(1):75.
- 287 10. Megersa BS, Bussmann H, Bärnighausen T, Muche AA, Alemu K, Deckert A. Community  
288 cervical cancer screening: Barriers to successful home-based HPV self-sampling in Dabat  
289 district, North Gondar, Ethiopia. A qualitative study. *PLOS ONE*. 2020 Dec  
290 11;15(12):e0243036.
- 291 11. Bakiewicz A, Rasch V, Mwaiselage J, Linde DS. “The best thing is that you are doing it for  
292 yourself” – perspectives on acceptability and feasibility of HPV self-sampling among cervical  
293 cancer screening clients in Tanzania: a qualitative pilot study. *BMC Women's Health*. 2020  
294 Dec;20(1):65.
- 295 12. Brandt T, Wubneh SB, Handebo S, Debalkie G, Ayanaw Y, Alemu K, et al. Genital self-  
296 sampling for HPV-based cervical cancer screening: a qualitative study of preferences and  
297 barriers in rural Ethiopia. *BMC Public Health*. 2019 Jul 31;19(1):1026.
- 298 13. Woo YL, Gravitt P, Khor SK, Ng CW, Saville M. Accelerating action on cervical screening  
299 in lower- and middle-income countries (LMICs) post COVID-19 era. *Prev Med*. 2021  
300 Mar;144:106294.
- 301 14. Mitchell SM, Pedersen HN, Eng Stime E, Sekikubo M, Moses E, Mwesigwa D, et al. Self-  
302 collection based HPV testing for cervical cancer screening among women living with HIV



- 303 in Uganda: a descriptive analysis of knowledge, intentions to screen and factors associated  
304 with HPV positivity. *BMC Women's Health*. 2017 Dec;17(1):4.
- 305 15. Mungo C, Barker E, Randa M, Ambaka J, Osongo CO. Integration of cervical cancer  
306 screening into HIV/AIDS care in low-income countries: a moral imperative.  
307 *Ecancermedicalscience*. 2021 May 20;15:1237.
- 308 16. Bouabida K, Chaves BG, Anane E. Challenges and barriers to HIV care engagement and  
309 care cascade: viewpoint. *Front Reprod Health*. 2023 Jul 20;5:1201087.
- 310 17. Luseno WK, Wechsberg WM, Kline TL, Ellerson RM. Health Services Utilization Among  
311 South African Women Living with HIV and Reporting Sexual and Substance-Use Risk  
312 Behaviors. *AIDS Patient Care STDS*. 2010 Apr;24(4):257–64.
- 313 18. Lofgren SM, Tsui S, Atuyambe L, Ankunda L, Komuhendo R, Wamala N, et al. Barriers to  
314 HIV Care in Uganda and Implications for Universal Test-and-Treat: A Qualitative Study.  
315 *AIDS Care*. 2022 May;34(5):597–605.
- 316 19. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of  
317 the global burden of cervical cancer associated with HIV. *The Lancet Global Health*. 2021  
318 Feb;9(2):e161–9.
- 319 20. Sarah Maria N, Olwit C, Kaggwa MM, Nabirye RC, Ngabirano TD. Cervical cancer  
320 screening among HIV-positive women in urban Uganda: a cross sectional study. *BMC*  
321 *Women's Health*. 2022 May 10;22(1):148.
- 322 21. Ndejjo R, Mukama T, Musabyimana A, Musoke D. Uptake of Cervical Cancer Screening  
323 and Associated Factors among Women in Rural Uganda: A Cross Sectional Study. *PLoS*  
324 *One*. 2016;11(2):e0149696.
- 325 22. Huchko MJ, Maloba M, Nakalembe M, Cohen CR. The time has come to make cervical  
326 cancer prevention an essential part of comprehensive sexual and reproductive health  
327 services for HIV-positive women in low-income countries. *Journal of the International*  
328 *AIDS Society*. 2015;18(6S5):20282.
- 329 23. Patridge EF, Bardyn TP. Research Electronic Data Capture (REDCap). *J Med Libr Assoc*  
330 [Internet]. 2018 Jan 12 [cited 2023 Jun 23];106(1). Available from:  
331 <http://jmla.pitt.edu/ojs/jmla/article/view/319>
- 332 24. World Health Organization. Improving data for decision-making: a toolkit for cervical  
333 cancer prevention and control programmes [Internet]. Geneva: World Health Organization;  
334 2018 [cited 2023 Jun 23]. 289 p. Available from:  
335 <https://apps.who.int/iris/handle/10665/279420>
- 336 25. Andrade C. The P Value and Statistical Significance: Misunderstandings, Explanations,  
337 Challenges, and Alternatives. *Indian J Psychol Med*. 2019;41(3):210–5.
- 338 26. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna,  
339 Austria; 2023. Available from: <https://www.R-project.org/>
- 340 27. Fitzpatrick M, Pathipati MP, McCarty K, Rosenthal A, Katzenstein D, Chirenje ZM, et al.  
341 Knowledge, attitudes, and practices of cervical Cancer screening among HIV-positive and  
342 HIV-negative women participating in human papillomavirus screening in rural Zimbabwe.  
343 *BMC Women's Health*. 2020 Jul 25;20(1):153.
- 344 28. Stuart A, Obiri-Yeboah D, Adu-Sarkodie Y, Hayfron-Benjamin A, Akorsu AD, Mayaud P.  
345 Knowledge and experience of a cohort of HIV-positive and HIV-negative Ghanaian women  
346 after undergoing human papillomavirus and cervical cancer screening. *BMC Women's*  
347 *Health*. 2019 Oct 23;19(1):123.



- 348 29. Usman IM, Chama N, Aigbogun Jr EO, Kabanyoro A, Kasozi KI, Usman CO, et al.  
349 Knowledge, Attitude, and Practice Toward Cervical Cancer Screening Among Female  
350 University Students in Ishaka Western Uganda. *Int J Womens Health*. 2023 Apr 14;15:611–  
351 20.
- 352 30. Mukama T, Ndejjo R, Musabyimana A, Halage AA, Musoke D. Women’s knowledge and  
353 attitudes towards cervical cancer prevention: a cross sectional study in Eastern Uganda.  
354 *BMC Womens Health*. 2017 Jan 31;17(1):9.
- 355 31. Perry S, Fair CD, Burrowes S, Holcombe SJ, Kalyesubula R. Outsiders, insiders, and  
356 intermediaries: village health teams’ negotiation of roles to provide high quality sexual,  
357 reproductive and HIV care in Nakaseke, Uganda. *BMC Health Services Research*. 2019 Aug  
358 13;19(1):563.
- 359 32. Musinguzi LK, Turinawe EB, Rwemisisi JT, de Vries DH, Mafigiri DK, Muhangi D, et al.  
360 Linking communities to formal health care providers through village health teams in rural  
361 Uganda: lessons from linking social capital. *Human Resources for Health*. 2017 Jan  
362 11;15(1):4.
- 363 33. Turinawe EB, Rwemisisi JT, Musinguzi LK, de Groot M, Muhangi D, de Vries DH, et al.  
364 Selection and performance of village health teams (VHTs) in Uganda: lessons from the  
365 natural helper model of health promotion. *Human Resources for Health*. 2015 Sep  
366 7;13(1):73.
- 367 34. Babughirana G, Gerards S, Mokori A, Nangosha E, Kremers S, Gubbels J. Maternal and  
368 newborn healthcare practices: assessment of the uptake of lifesaving services in Hoima  
369 District, Uganda. *BMC Pregnancy and Childbirth*. 2020 Nov 11;20(1):686.
- 370 35. Filade TE, Dareng EO, Olawande T, Fagbohun TA, Adebayo AO, Adebamowo CA.  
371 Attitude to Human Papillomavirus Deoxyribonucleic Acid-Based Cervical Cancer Screening  
372 in Antenatal Care in Nigeria: A Qualitative Study. *Front Public Health*. 2017;5:226.
- 373 36. Kuczborska K, Kacperczyk-Bartnik J, Wolska M, Pluta M, Bartnik P, Dobrowolska-Redo A,  
374 et al. Secondary cervical cancer prevention in routine prenatal care — coverage, results and  
375 lessons for the future. *Ginekologia Polska*. 2019;90(7):396–402.
- 376 37. Brun-Micaleff E, Coffy A, Rey V, Didelot MN, Combecal J, Doutre S, et al. Cervical cancer  
377 screening by cytology and human papillomavirus testing during pregnancy in french women  
378 with poor adhesion to regular cervical screening. *Journal of Medical Virology*.  
379 2014;86(3):536–45.
- 380 38. Tchounga B, Boni SP, Koffi JJ, Horo AG, Tanon A, Messou E, et al. Cervical cancer  
381 screening uptake and correlates among HIV-infected women: a cross-sectional survey in  
382 Côte d’Ivoire, West Africa. *BMJ Open*. 2019 Aug;9(8):e029882.
- 383 39. White HL, Meglioli A, Chowdhury R, Nuccio O. Integrating cervical cancer screening and  
384 preventive treatment with family planning and HIV-related services. *Int J Gynecol Obstet*.  
385 2017 Jul;138:41–6.
- 386 40. Ninsiima M, Nyabigambo A, Kagaayi J. Acceptability of integration of cervical cancer  
387 screening into routine HIV care, associated factors and perceptions among HIV-infected

- 388 women: a mixed methods study at Mbarara Regional Referral Hospital, Uganda. BMC  
389 Health Serv Res. 2023 Apr 3;23(1):333.
- 390 41. Uganda Population-Based HIV Impact Assessment [Internet]. PHIA Project; 2022 [cited  
391 2023 July 2]. Available from: [https://phia.icap.columbia.edu/wp-](https://phia.icap.columbia.edu/wp-content/uploads/2022/08/UPHIA-Summary-Sheet-2020.pdf)  
392 [content/uploads/2022/08/UPHIA-Summary-Sheet-2020.pdf](https://phia.icap.columbia.edu/wp-content/uploads/2022/08/UPHIA-Summary-Sheet-2020.pdf)
- 393 42. Rosenman R, Tennekoon V, Hill LG. Measuring bias in self-reported data. Int J Behav  
394 Healthc Res. 2011 Oct;2(4):320–32.
- 395 43. Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment  
396 methods. JMDH. 2016 May;211.  
397

398 **Table 1.** Demographics stratified by HIV status

	<b>Overall</b>	<b>HIV-positive</b>	<b>HIV-negative</b>	
	N = 1437	N = 127	N = 1310	<b>p-value</b>
	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	
<b>Survey Language</b>				< 0.001
English	38 (2.6)	14 (11.0)	24 (1.8)	
Lusoga	1399 (97.4)	113 (89.0)	1286 (98.2)	
<b>Age</b>				0.143
30-34	612 (42.6)	47 (37.0)	565 (43.1)	
35-39	319 (22.2)	35 (27.6)	284 (21.7)	
40-44	249 (17.3)	17 (13.4)	232 (17.7)	
45-49	257 (17.9)	28 (22.0)	229 (17.5)	
<b>Education</b>				0.123
No Education	451 (31.4)	50 (39.4)	401 (30.6)	
Primary Education or more	976 (67.9)	76 (59.8)	900 (68.7)	
<i>Missing</i>	<i>10 (0.7)</i>	<i>1 (0.8)</i>	<i>9 (0.7)</i>	
<b>Occupation</b>				0.060
Farmer	1216 (84.6)	99 (78.0)	1117 (85.3)	
Other	178 (12.4)	21 (16.5)	157 (12.0)	
<i>Missing</i>	<i>43 (3.0)</i>	<i>7 (5.5)</i>	<i>36 (2.7)</i>	
<b>Relationship Status</b>				0.865
Married/In a relationship	1243 (86.5)	107 (84.3)	1136 (86.7)	
Single	116 (8.1)	12 (9.4)	104 (7.9)	
Separated/Divorced/Widowed	77 (5.4)	8 (6.3)	69 (5.3)	
<i>Missing</i>	<i>1 (0.1)</i>	<i>0 (0.0)</i>	<i>1 (0.1)</i>	
<b>Partner Education</b>				0.813
No Education	189 (13.2)	17 (13.4)	172 (13.1)	
Primary Education or more	1037 (72.2)	89 (70.1)	948 (72.4)	
<i>Missing</i>	<i>211 (14.7)</i>	<i>21 (16.5)</i>	<i>190 (14.5)</i>	
<b>Age at first pregnancy</b>				0.16
< 16	262 (43.3)	28 (35.4)	234 (44.5)	
≥ 16	313 (51.7)	45 (57.0)	268 (51.0)	
<i>Missing</i>	<i>25 (4.1)</i>	<i>4 (5.1)</i>	<i>21 (4.0)</i>	
<b>Number of pregnancies</b>				0.875
1-6	40 (2.8)	28 (35.4)	255 (48.5)	
7-12	256 (17.8)	21 (16.5)	235 (17.9)	
≥ 13	1141 (79.4)	103 (81.1)	1038 (79.2)	

399

400


401 **Table 2.** Results of survey on attendance to healthcare services stratified by HIV status

	Health Outreach			Health Centre		
	HIV+	HIV-	p-value	HIV+	HIV-	p-value
	N = 127 <i>n (%)</i>	N = 1310 <i>n (%)</i>		N = 127 <i>n (%)</i>	N = 1310 <i>n (%)</i>	
<b>Attendance</b>	113 (89.0)	1124 (85.8)	0.596	122 (96.1)	1267 (96.7)	0.239
<b>Services Accessed</b>						
Antenatal Care	47 (37.0)	517 (39.5)	0.655	79 (62.2)	839 (64.0)	0.752
HIV	40 (31.5)	116 (8.9)	<0.001	41 (32.3)	147 (11.2)	<0.001
Family Planning	30 (23.6)	315 (24.0)	1.000	28 (22.0)	311 (23.7)	0.749
Immunizations	59 (46.5)	551 (42.1)	0.388	38 (29.9)	308 (23.5)	0.132

402

403

404 **Figure 1.** Common barriers to cervical cancer screening stratified by HIV status



405

406

407